Latest Breaking News On - Navidea biopharmaceuticals - Page 8 : comparemela.com

NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc (NAVB)

NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc (NAVB)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesExchange commissionAmerican company guide theCompany of the panelNavidea biopharmaceuticals incNyse americanNavidea biopharmaceuticalsListings qualifications panelCompany guide

StockNews com Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of Navidea Biopharmaceuticals stock opened at $0.09 on Tuesday. The firm has a market capitalization of $9.32 million, a PE ratio […]

Allred capital managementTherapeutic development programsNavidea biopharmaceuticals company profileRenaissance technologiesNavidea biopharmaceuticals incNavidea biopharmaceuticalsFree reportGet free reportCapital managementState street corpStreet corpDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals dailyNyse navbInitiated coverage

StockNews com Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Sunday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.11 on Friday. The firm has a market cap of $11.38 million, a PE ratio of -0.39 and a beta of […]

Navidea biopharmaceuticals company profileNavidea biopharmaceuticals incAllred capital managementRenaissance technologiesTherapeutic development programsNavidea biopharmaceuticalsFree reportGet free reportStreet corpCapital managementDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals dailyNyse navbInitiated coverageStocknews com

Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Saturday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Trading Up 23.4 % Shares of NAVB opened at $0.10 on Friday. Navidea Biopharmaceuticals has a 12 month low of $0.06 and a 12 […]

Navidea biopharmaceuticals company profileRenaissance technologiesTherapeutic development programsNavidea biopharmaceuticals incAllred capital managementNavidea biopharmaceuticalsFree reportGet free reportStreet corpCapital managementDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals dailyNyse navbInitiated coverageStocknews com

StockNews com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

StockNews com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Allred capital managementNavidea biopharmaceuticals incRenaissance technologiesTherapeutic development programsNavidea biopharmaceuticalsGet free reportCapital managementStreet corpDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals daily